A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia

Intern Med J. 2009 Apr;39(4):269-71. doi: 10.1111/j.1445-5994.2009.01905.x.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / economics
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chlorambucil / therapeutic use
  • Conflict of Interest
  • Cost-Benefit Analysis
  • Cross-Over Studies
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / economics
  • Disease-Free Survival
  • Drug Costs
  • Hospital Costs
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / economics
  • Practice Guidelines as Topic*
  • Prognosis
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Vidarabine / administration & dosage
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives
  • Vidarabine / economics
  • Vidarabine / therapeutic use

Substances

  • Antimetabolites, Antineoplastic
  • Chlorambucil
  • Cyclophosphamide
  • Vidarabine
  • fludarabine